We are international
Donate
• health professionals TEXT SIZE   

For other announcements of interest to the medical community, choose a subcategory from the menu on the left.

IMF - Professionals

The IMF at ASCO 2007
Webcasts from the 43rd Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.

STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
Data Presented at the ASCO Cancer Conference

New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
In an article entitled "The Legacy of the World Trade Center Dust," physicians say more than 5 years after the World Trade Center disaster, "uncertainty and controversy remain about the health risks posed by inhaling dust, the subsequent fires and the cleanup effort."

Use of Bisphosphonates in Multiple Myeloma: International Myeloma Working Group (IMWG) Response to Mayo Clinic Consensus Statement
The IMWG, which is comprised of 85 investigators specializing in the area of multiple myeloma, has reviewed and considered the recent Mayo Clinic consensus statement for the use of bisphosphonates (BPs) in multiple myeloma. Although the IMWG is in general agreement with the Mayo consensus statement, several important issues have been raised.

CAUTION ABOUT USE OF ERYTHROPOIETIN PRODUCTS
Several recent public health advisories and safety messages have raised cautions about the use of Darbopoetin alfa (Aranesp®) and Epoetin alfa (Procrit® and Epogen®). These drugs are used to stimulate red blood cell production to reverse anemia.

Treatment of Newly Diagnosed Myeloma Based on Mayo Clinic's mSMART
mSmart (Mayo Stratification of Myeloma and Risk-Adapted Therapy).
This consensus statement from the Mayo Clinic is excellent overview of the issues and a good basis for discussion as the scientific and clinical communities work to advance the standard of care.

'International uniform response criteria for myeloma' published in journal Leukemia
This article is the result of the efforts of the International Myeloma Working Group.

Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
A multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of myeloma reviewed available data concerning the use of bisphosphonates. Guidelines for the use of bisphosphonates in MM were developed. This link is to the full article.

Myeloma Management Guidelines: A Consensus Report from the Scientific Advisors of the IMF
These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. This article appeared in The Hematology Journal (2003) 4, 379-398.